



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Lupin receives U.S. FDA approval for Hydrocortisone Valerate Cream

Mumbai, Baltimore, August 16, 2019: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Hydrocortisone Valerate Cream USP, 0.2% from the United States Food and Drug Administration (U.S. FDA).

Lupin's Hydrocortisone Valerate Cream USP, 0.2%, is the generic version of Westcort® Cream, 0.2%, of Sun Pharmaceutical Industries, Inc. It is indicated for the relief of the Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients.

Hydrocortisone Valerate Cream USP, 0.2%, (RLD: Westcort®) had an annual sales of approximately USD 15 million in the US (IQVIA MAT March 2019).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8th largest generics pharmaceutical company by revenues (31st Mar 2019, Bloomberg LTM) respectively. The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT Jun 2019); 3rd largest Indian pharmaceutical company by global revenues (31st Mar 2019, Bloomberg LTM); 5th largest generic pharmaceutical player in Japan and 6th largest company in the Indian Pharmaceutical Market (IQVIA MAT Jun 2019).

For the financial year ended 31st March, 2019, Lupin's Consolidated sales and Net profits were at Rs. 163,694 million (USD 2.34 billion) and Rs. 9,466 million (USD 136 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran
VP – Corporate Communications
Email: poojathakran@lupin.com
Ph: +91-22-66402531 / 8291013225

Arvind Bothra
Head – Investor Relations
Email: arvindbothra@lupin.com
Ph: +91-22-66408237

*Safe Harbor Statement

Westcort® is a registered trademark of Sun Pharmaceutical Industries Inc.